Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)

NCT03740529 is registered in ClinicalTrials.gov with Loxo Oncology, Inc. as lead sponsor.

NCT NCT03740529
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03740529 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)
Lead sponsor
Loxo Oncology, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
March 15, 2019
Completion date
December 23, 2025
Enrollment
803 (actual)
Sites
56

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell lymphoma, chronic lymphocytic leukemia, mantle cell lymphoma, marginal zone lymphoma, small lymphocytic lymphoma, waldenstrom macroglobulinemia